This will reduce the healthcare expenditure, per capita.
A great counterexample would be the USA — which despite the highest global expenditure, per citizien, has among the lowest life expectancies / healthcare outcomes.
The US does not have "among the lowest" life expectancy. We're just out of the top quartile. And that has less to do with the quality of American health care and more to do with obesity and sedentary lifestyles. I expect with the more widespread introduction of GLP-1 receptor agonists you're going to see a jump in American longevity.
Everyone in the US has access to healthcare. We have programs that cost little or nothing, depending on your income. Beyond that, we have EMTALA, which means the ER can't turn you away even if you never bothered to sign up.
A great counterexample would be the USA — which despite the highest global expenditure, per citizien, has among the lowest life expectancies / healthcare outcomes.